The surge in ADHD prescriptions across Ontario over the past decade is impossible to ignore. A 157 percent increase in less than ten years, with adults particularly women driving much of the growth, raises an uncomfortable but necessary question: is this a long-overdue correction in diagnosis, or are we moving too fast toward medication as a default solution?
According to a recent study published in JAMA Network Open, prescriptions for stimulant medications such as Ritalin and Adderall rose sharply between 2015 and 2023, with a dramatic acceleration during the COVID-19 pandemic. The lockdown years, marked by disrupted routines, increased screen time, and mounting mental health pressures, appear to have acted as a catalyst. In 2020 alone, new stimulant prescriptions jumped by 28 percent four times the annual growth rate seen in the years before the pandemic.
On one hand, this trend reflects progress. For decades, ADHD was narrowly defined through the lens of hyperactive young boys. Quiet children especially girls who struggled with inattention, disorganization, or mental restlessness were often overlooked. Many women are now being diagnosed in their 20s, 30s, or even 40s, finally putting a name to challenges they have lived with their entire lives. For them, increased access to diagnosis and treatment can be life-changing.
The numbers tell this story clearly. Women aged 25 to 44 saw a staggering 421 percent increase in ADHD prescriptions, compared to 220 percent among men of the same age. Similar patterns are emerging among younger adults and adolescents, as well as in provinces like British Columbia, where adult ADHD diagnoses more than doubled during the pandemic and continue to rise.
But progress should not blind us to risk.
The rapid expansion of stimulant use also raises red flags about over-diagnosis and misdiagnosis. ADHD symptoms can overlap with anxiety, depression, trauma, sleep disorders, or even burnout conditions that surged during the pandemic years. Without careful assessment, there is a real danger that medication is being used to treat distress rooted in broader social and psychological pressures.
Researchers themselves have acknowledged the gaps. There is limited data on whether stimulant medications are always being prescribed appropriately, particularly in adults. In a healthcare system already stretched thin, quick prescriptions can sometimes replace comprehensive evaluations, therapy, or lifestyle interventions.
Children’s prescription rates are also climbing, especially among girls, which again reflects better recognition but also demands caution. Medication can be helpful, even essential, but it should never be the only answer offered.
What this moment calls for is balance. Better training for clinicians in adult ADHD diagnosis. Clear, evidence-based guidelines. And a broader public conversation about attention, productivity, and mental health in a world that constantly competes for our focus.
ADHD is real. It affects nearly two million Canadians, and for many, treatment opens doors that were long closed. But as prescriptions soar, we must ensure that awareness does not turn into overreach and that care remains thoughtful, individualized, and humane.
Because seeing ADHD clearly means more than just writing a prescription.
